ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Osnat Elyashiv, Jonathan A. Ledermann, Gita Parmar, Laura Farrelly, Nicholas Counsell, Amanda Feeney, Fatima El-Khouly, Ian Macdonald, Andreia Neto, Esther Arthur-Darkwa, Eva Burnett, Gordon C. Jayson, Linda Mileshkin, Charlie Gourley, Shibani Nicum
Topics & Concepts
OlaparibMedicineOncologyInternal medicineOvarian cancerMaintenance therapyRandomized controlled trialClinical endpointChemotherapyCancerPolymeraseBiochemistryGeneChemistryPoly ADP ribose polymerasePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies